FDA issues warning on Celgene’s cancer drug Revlimid

<p><img alt="Celgene is a publicly traded multi-national biopharmaceutical association that says it had $4.8 billion in revenues in 2011." src="http://medicalinfo.info/wp-content/plugins/RSSPoster_PRO/cache/3280d_celgene_t220.png" /></p><p>Celgene is a publicly traded multi-national biopharmaceutical association that says it had $4.8 billion in revenues in 2011.
</p>

<p> Celgene</p>

<p>The Food and Drug Administration has released a <a href="http://www.fda.gov/Drugs/DrugSafety/ucm302939.htm">safety update</a> on Revlimid, a cancer drug marketed by <a href="http://www.celgene.com/index.aspx">Celgene Corp</a>., a multi-national biopharmaceutical association that has a investigate core in San Diego. In a statement, a FDA pronounced it “is informing a open of an increasing risk of second primary malignancies (new forms of cancer) in patients with newly-diagnosed <a href="http://www.ncbi.nlm.nih.gov/pubmedhea...